## Abstract ## BACKGROUND. Interferon‐alpha (IFN‐α) confers a survival advantage for the minority of patients with chronic myeloid leukemia (CML) who achieve a complete cytogenetic response. The question of whether IFN‐α‐responsive patients can experience further improvements with imatinib has not
Cytogenetic remissions induced by interferon α and imatinib mesylate are immunologically distinct in chronic myeloid leukemia
✍ Scribed by Shin Nakayama; Tokiko Nagamura-Inoue; Kazuaki Yokoyama; Nobuhiro Ohno; Jun Ooi; Satoshi Takahashi; Kaoru Uchimaru; Toru Iseki; Arinobu Tojo
- Book ID
- 105682878
- Publisher
- Carden Jennings Publishing
- Year
- 2007
- Tongue
- English
- Weight
- 124 KB
- Volume
- 86
- Category
- Article
- ISSN
- 0925-5710
No coin nor oath required. For personal study only.
📜 SIMILAR VOLUMES
## Abstract ## BACKGROUND Myelosuppression occurs in up to 50% of patients with chronic myeloid leukemia (CML) who are treated with imatinib and ≥ Grade 3 myelosuppression is reported in approximately 10% of patients. ## METHODS The authors investigated the prognostic significance of anemia occu
A patient with chronic eosinophilic leukemia and a unique complex chromosomal translocation 46,XY,t(3;9;5)(q25;q34;q33) who had elevated blood interleukin-5 is reported. Complete cytogenetic remission was induced by interferon-␣ after treatment failure with corticosteroids and cytotoxic drugs. Sever